Loading organizations...
Curevo Vaccine is a clinical-stage biotechnology company based in Seattle, Washington, that develops subunit vaccines to prevent shingles and chickenpox in adults and children. The company's lead candidate, amezosvatein, utilizes a non-living viral component and proprietary adjuvant technology to target the $7 billion varicella zoster virus market. Curevo has secured significant capital to advance its clinical trials, including an $86 million Series A round and a $110 million Series B financing in early 2025. The organization is backed by prominent institutional investors such as RA Capital Management, Medicxi, OrbiMed, and Sanofi Ventures. These funds support ongoing research and the upcoming mid-2025 launch of an extension trial for its shingles vaccine. Curevo Vaccine was founded in 2018 as a partnership between GC Pharma, the Mogam Institute for Biomedical Research, and the Infectious Disease Research Institute.
Curevo has raised $196.0M across 3 funding rounds.
Curevo has raised $196.0M in total across 3 funding rounds.
Curevo has raised $196.0M in total across 3 funding rounds.
Curevo's investors include Medicxi, BoxOne Ventures, Ali Tamaseb, RA Capital Management.
Curevo has raised $196.0M across 3 funding rounds. Most recently, it raised $110.0M Series B in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2025 | $110M Series B | Medicxi | BoxOne Ventures, ALI Tamaseb | Announced |
| Nov 1, 2022 | $26M Series A | — | BoxOne Ventures, ALI Tamaseb | Announced |
| Jan 1, 2022 | $60M Series A | RA Capital Management | BoxOne Ventures, ALI Tamaseb | Announced |
Curevo Vaccine is a clinical-stage biotechnology company headquartered in Bothell, near Seattle, Washington, focused on developing next-generation non-mRNA adjuvanted subunit vaccines to reduce the burden of infectious diseases, emphasizing improved tolerability, efficacy, and accessibility.[1][2][4] Its lead product, amezosvatein, is a prophylactic vaccine targeting shingles (herpes zoster), a painful condition caused by varicella zoster virus reactivation, with Phase 2 trials showing promise against competitors like Shingrix by enhancing tolerability while maintaining high efficacy.[1][5][6] Curevo serves populations at risk of shingles, particularly adults over 50, addressing unmet needs in vaccine side effects and global supply; recent momentum includes a $110 million funding round in March 2025 to advance trials, positive Phase 2 data updates in January 2025, and enrollment in a Phase 2 extension trial of 640 participants in June 2025.[1][3][6]
Founded in 2018, Curevo emerged from expertise in protein science, adjuvant technology, and immunology, with early backing from GC Biopharma (formerly Green Cross Corporation), a South Korean firm with decades of vaccine manufacturing experience.[1][3][4] The company assembled a multidisciplinary team, including CEO George Simeon and Chief Medical Officer Guy De La Rosa, alongside scientific advisors, to tackle infectious diseases starting with shingles and chickenpox.[3][4] Pivotal early traction came through Phase 1 and 2 trials for amezosvatein launched in 2019 and 2022, respectively, culminating in the landmark $110M raise in 2025, which brought on high-profile advisors like Dr. Moncef Slaoui (former Operation Warp Speed chief) and Tal Zaks, validating its non-mRNA approach amid mRNA dominance.[1][3][5]
Curevo stands out in vaccine development through:
Curevo rides the post-mRNA vaccine wave, capitalizing on tolerability backlash from COVID-era shots and Shingrix's high efficacy but frequent side effects (e.g., pain in 10-18% with postherpetic neuralgia risk).[1][4] Timing aligns with aging populations driving shingles demand—1 in 3 lifetime risk—and supply gaps in emerging markets, where non-mRNA tech enables low-cost, stable manufacturing without cold chains.[1][2] Market tailwinds include biopharma's shift to adjuvants for broader infectious disease threats (e.g., HPV, malaria parallels), bolstered by GC Biopharma's global footprint.[1] Curevo influences the ecosystem by proving subunit vaccines' viability, potentially pressuring incumbents like GSK (Shingrix maker) and fostering investment in protein-adjuvant innovation.[3]
Curevo's trajectory points to Phase 3 initiation post-2025 funding, with amezosvatein potentially capturing shingles market share through superior patient compliance if tolerability data holds.[1][6] Trends like adjuvant advancements and rare disease expansion (via GC partners) will shape growth, alongside regulatory wins in the US and South Korea.[1][3] Its influence could evolve from niche challenger to ecosystem leader, humanizing biotech by making vaccines accessible and side-effect-free—echoing its founding pledge to cut infectious disease burdens where current options fall short.[4]
